Echo Therapeutics Inc.’s (OTC:ECTE) grew more than three fold in Q2 as the company poured money into research & development and administrative expenses.

Losses for the quarter widened 262 percent to $1.9 million, or a loss of 6 cents per diluted share, during the three months ended June 30, compared to losses of $536,000, or 2 cents lost per diluted share, during the same period last year.